Bristol Myers Squibb Company $BMY Stock Position Raised by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,092,316 shares of the biopharmaceutical company’s stock after acquiring an additional 10,639 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Bristol Myers Squibb were worth $50,563,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Tweedy Browne Co LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $333,000. Arista Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $463,000. Stratos Wealth Partners LTD. boosted its stake in shares of Bristol Myers Squibb by 1.4% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 206,934 shares of the biopharmaceutical company’s stock worth $9,579,000 after acquiring an additional 2,851 shares in the last quarter. Angeles Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 10.4% during the 2nd quarter. Angeles Wealth Management LLC now owns 14,983 shares of the biopharmaceutical company’s stock worth $694,000 after acquiring an additional 1,406 shares in the last quarter. Finally, Riverbend Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 8.7% during the 2nd quarter. Riverbend Wealth Management LLC now owns 8,031 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 646 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $43.63 on Friday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The business has a fifty day simple moving average of $46.07 and a 200 day simple moving average of $47.55. The firm has a market cap of $88.80 billion, a price-to-earnings ratio of 17.59, a P/E/G ratio of 2.25 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the company earned $2.07 earnings per share. Bristol Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BMY shares. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Tuesday, August 5th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $57.23.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.